Roche's Tecentriq wins U.S. approval for aggressive breast cancer

Swiss drugmaker Roche on Friday won U.S. Food and Drug Administration (FDA) approval of its immunotherapy Tecentriq for triple-negative breast cancer, an aggressive form of the disease that has proven tough-to-treat.